International Journal of Scientific Research and Engineering Development-– Volume 8 Issue 2, Mar-Apr 2025
Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

Guillain-Barré syndrome: A Comprehensive Review

K.Vedith Reddy[1*], P.Akhila[1], S.Veena[1], K.Harshitha[1], Dr. K.Tirumala Naik[2]
[1]Pharm. D Interns, Krishna Teja Pharmacy College, Tirupathi, Andhra Pradesh.
[2]Associate professor, Head Clinical Preceptor, Department of Pharmacy Practise, Krishna Teja Pharmacy College, Tirupathi, Andhra Pradesh.

Abstract
Guillain-Barré syndrome (GBS) is an acute autoimmune polyradiculoneuropathy that primarily affects the peripheral nervous system, leading to rapidly progressing muscle weakness and, in severe cases, respiratory failure and autonomic dysfunction. The exact etiology is not fully understood, but GBS is strongly associated with preceding infections, particularly *Campylobacter jejuni*, Cytomegalovirus, and Epstein-Barr virus. Molecular mimicry is believed to play a significant role in the immune-mediated attack on peripheral nerves. Diagnosis is based on clinical presentation, cerebrospinal fluid analysis, and electrophysiological studies. The management of GBS involves supportive care, immunotherapy with intravenous immunoglobulin (IVIG) or plasma exchange, and rehabilitation. Although most patients recover, some experience long-term neurological deficits. This review provides a comprehensive overview of the epidemiology, etiology, pathogenesis, clinical presentation, diagnostic approaches, complications, and treatment strategies for GBS.

Keywords: **Guillain-Barré syndrome, autoimmune neuropathy, peripheral nervous system, molecular mimicry, *Campylobacter jejuni*, immunoglobulin therapy, plasma exchange, nerve conduction studies, cerebrospinal fluid analysis, respiratory failure**.

Introduction:
Guillain-Barré syndrome (GBS) is an autoimmune polyradiculoneuropathy that mostly presents clinically as muscle weakness and is characterized by severe inflammation that damages the peripheral nerve system in a fast-progressing pattern. The symptom may appear suddenly or gradually over the course of a few days to a few weeks[1,2].

The disease's severity varies greatly and can range from mild to extremely severe, which can result in major morbidities and even death, including tetraplegia, respiratory failure, and autonomic dysfunction. It is estimated that between two and three percent of patients in wealthy nations die from GBS[3,4].

The clinical consequences that patients typically experience are the primary basis for diagnosing GBS. This involves the onset of muscle weakness in the lower limbs, diminished or non-existent deep reflexes, and the disease's monophasic pattern. Additionally, cerebrospinal fluid analysis and nerve conductivity studies are crucial diagnostic procedures that can support the diagnosis[5,6].

Epidemiology:
GBS's annual incidence rate has gone up with age (0.06/100,000 for children and 27/100,000 for elderly people 80 years of age and older), and men are marginally more likely than women to get the illness[10]. Previous research has shown that the incidence of GBS in people of all ages ranges from 0.16 to 0.4/100,000 year, according to numerous international surveys[2,11]. There have been reports of seasonal variations, most likely as a result of shifting infectious antecedents, but these results are rarely statistically significant[12].

Etiology:
Guillain-Barré syndrome (GBS) and its variations are classified as immune-mediated neuropathies that occur after an infection. Animal models provide evidence that molecular mimicry plays a significant impact. A lipooligosaccharide found in the outer membrane of Campylobacter jejuni bacteria is comparable to gangliosides, which are parts of peripheral nerves, in gastrointestinal infections caused by the bacterium. Consequently, a cross-reaction on host neurons may result from an immune response that is triggered to combat infection[7].

GBS has been related to a number of infections. The most prevalent are respiratory or gastrointestinal disorders. In the one to six weeks prior to the onset of GBS, up to 70% of patients reported having an antecedent sickness.

Cytomegalovirus and a typical bacterium called Mycoplasma are among the microorganisms that cause respiratory illnesses and can subsequently cause GBS[9].

Another potential trigger is the Epstein-Barr virus, which causes infectious mononucleosis. GBS has been associated with the virus that causes acquired immune deficiency syndrome. It can happen as quickly as a few weeks after the initial infection and typically happens in the early stages of a human immunodeficiency virus infection, before the immune system has been seriously weakened[13].

Risk Factors:

People of various ages can be impacted by GBS. However, as people age, the danger rises. It is more likely to affect men than women. HIV, the virus that causes AIDS, Mycoplasma pneumonia, surgery, trauma, Hodgkin's lymphoma, influenza vaccinations or childhood vaccinations, Zika virus, cytomegalovirus, Epstein-Barr virus, hepatitis A, B, C, and E, and campylobacter, a type of bacteria frequently found in undercooked poultry, can all cause GBS[14].

Complications:

Up to 22% of GBS patients need machine-assisted breathing support for a brief period of time during the first week of treatment. Most GBS patients either fully recover or just experience mild residual tingling, numbness, or paralysis. Blood pressure swings and abnormal heartbeats, or cardiac arrhythmias, are known side effects of GBS[15].

One-third of patients experience severe nerve pain, which can be relieved with medication. Being immobile also increases the likelihood of developing bedsores (pressure sores), but frequent repositioning may help prevent this problem. Those who are unable to move due to GBS may be advised to take blood thinners and wear support stockings until they are able to walk independently. GBS can cause sluggish bowel function and urinary retention[16].

Pathogenesis:

Understanding GBS, especially the axonal variety, is greatly aided by molecular mimicry. Campylobacter jejuni's lipooligosaccharide resembles the gangliosides found in peripheral nerve membranes[7].

Most cases of GBS are believed to be immune-mediated demyelinating neuropathy, which typically manifests as an abrupt onset. About two-thirds of cases start with an acute influenza-like sickness that the patient has already recovered from by the time the neuropathy appears. GBS is associated to infections with C. jejuni, Cytomegalovirus, Epstein–Barr virus, and Mycoplasma pneumoniae, as well as prior vaccination[17].

Segmental demyelination brought on by activated macrophages sets off an immunological response mediated by T cells. The lesions are comparable when these T-cells are given to an uninitiated animal. Additionally, it has been demonstrated that lymphocytes from GBS patients demyelinate myelinated nerve fiber tissue cultures. Blood-stream antibodies that react with peripheral nerve components may also be involved[18].

Sign and Symptoms:

The most common cause of GBS is a respiratory infection that results in cold or influenza-like symptoms like fever, runny nose, cough, and generalized aches and pains; low-extremity weakness that spreads to the upper body; difficulty walking or climbing stairs; difficulty with facial movements, speaking, chewing, and swallowing; dual vision and erroneous eye movement; severe pain that can be achy, shooting, or cramping in nature, and that is worse at night; problems with bladder or bowel function; tachycardia; low or high blood pressure; and trouble breathing[19].

Diagnosis:

GBS is diagnosed based on the clinical characteristics of rapidly developing weakness and loss of reflexes after an antecedent disease,

such as diarrhea or an upper respiratory tract infection[21].

Electrophysiologic investigations and cerebrospinal fluid examinations, which are obtained through spinal tap, are the most often used diagnostic tests (lumbar puncture). The findings of these tests are frequently positive, validating the clinical suspicion. Further testing might be necessary to rule out the potential of another illness masquerading as GBS if the diagnosis is still unclear[20]. when a person is suspected of having GBS, electrical testing is the next stage in the diagnostic process[22].

Therapeutic Strategies:

Immunological therapy and general medical care are both part of the multidisciplinary approach used to treat GBS. Monitoring of respiratory, cardiac, and hemodynamic function, prophylactic treatment for deep vein thrombosis, management of potential bladder and bowel dysfunction, early physiotherapy and rehabilitation initiation, and psychosocial support are all necessary to prevent or manage complications. Additionally, it's crucial to manage pain using opioids or non-steroidal anti-inflammatory medications[23].

Applicable treatments:

- Immunoglobulin therapy: Immunoglobulin containing healthy antibodies from blood donors is administered intravenously through a vein. High dosages of immunoglobulin can prevent the harmful antibodies that could cause GBS[24].
- Plasma exchange therapy, also known as plasmapheresis, involves extracting and separating the blood's liquid component, or plasma, from the blood cells. Following the reintroduction of the blood cells, the donor's body creates more plasma to make up for the lost amount. Antibodies from plasma that aid in the immune system's assault on peripheral nerves may be eliminated via plasmapheresis[25].

Conclusion:

We have examined the results of earlier research on the origin, pathophysiology, and therapy of GBS in this study. The most common factors that predispose people to developing GBS include viral infections. As a result, patients who are at risk should be provided with appropriate therapies. Immunoglobulin therapy and plasma exchange continue to be the most important and effective aspects of illness management.

References:

1.Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-66.

2.Cosi V, Versino M. Guillain-Barré syndrome. Neurol Sci. 2006;27(1):47-51

3. Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469-82.

4.Dornonville de la Cour C, Jakobsen J. Residual neuropathy in long-term population-based follow-up of Guillain-Barré syndrome. Neurology. 2005;64(2):246-53.

5. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27:21-4.

6.Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain J Neurol. 2014;137(1):33-43

7. Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993 Nov 01;178(5):1771-5

8. Dirlikov E, Major CG, Medina NA, Lugo-Robles R, Matos D, Muñoz-Jordan JL, Colon-Sanchez C, Garcia M, Olivero-Segarra M, Malave G, Rodríguez-Vega GM, Thomas DL, Waterman SH, Sejvar JJ, Luciano CA, Sharp TM, Rivera-García B. Clinical Features of Guillain-Barré Syndrome With vs Without Zika Virus Infection, Puerto Rico, 2016. JAMA Neurol. 2018 Sep 01;75(9):1089-1097.

9. Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barré syndrome: Expanding the

concept of molecular mimicry. Trends Immunol 2022;43:296-308.
10. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33
11. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opinion Neurol. 2001;14(5):605-13
12. Willison HJ, Jacobs BC, Van-Doorn PA. Guillain-Barré syndrome. Lancet 2016;388:717-27.
13. Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol 2021;11:587380
14. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbio Rev 1998;11:555-67.
15. Castillo MS. Physical therapy differential diagnosis for a patient with viral central nervous system infection in acute care: A case study. Philippine J Phys Ther 2022;1:1-13
16. Berg VD, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Doorn PA. Guillain Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014;10:469-82
17. Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin 2013;31:491-510.
18. Yang M, Peyret C, Shi XQ, Siron N, Jang JH, Wu S, et al. Evidence from human and animal studies: Pathological roles of CD8(+) T Cells in autoim periph neuropat. Front Immunol 2015;6:532
19. Parry GJ, Steinberg JS. Guillain-Barre Syndrome: From Diagnosis to Recovery. United States: Demos Medical Publishing; 2007
20. Doherty CM, Forbes RB. Diagnostic lumbar puncture. Ulster Med J 2014;83:93-102.
21. Piccione EA, Salame K, Katirji B. Guillain-Barré syndrome and related disorders. In: Katirji B, Kaminski H, Ruff R, editors. Neuromuscular Disorders in Clinical Practice. New York: Springer; 2014.
22. Sonoo M, Menkes DL, Bland J, Burke D. Nerve conduction studies and EMG in carpal tunnel syndrome: Do they add value? Clin Neurophysiol Pract 2018;3:78-88
23. Meena AK, Khadilkar SV, Murthy JM. Treatment guidelines for Guillain-Barré syndrome. Ann Indian Acad Neurol 2011;14:S73-81.
24. Kuwabara S, Mori M, Ogawara K, Hattori T, Oda S, Koga M, et al. Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24:54-8
25. Patten E. Therapeutic plasmapheresis and plasma exchange. Crit Rev Clin Lab Sci 1986;23:147-75.

